Contact
searchSearch
HMP Global

Multiple Sclerosis Topic Center

a head in profile with a heart over where the brain would be against a teal background
News
Multiple Sclerosis May Increase Risk for Alzheimer Disease
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
In Pediatric Onset Multiple Sclerosis, Biological Aging May Be Accelerated
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
Biomarker Combo Predicts MS in Patients With Radiologically Isolated Syndrome
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
Long COVID Symptoms Persist in Individuals With Multiple Sclerosis, Study Finds
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
Injectable Medication
News
MS Drug Associated with Rare Cases of Anaphylaxis, FDA Warns
02/06/2025
Jolynn Tumolo
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare,...
02/06/2025
Neurology
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
Jolynn Tumolo
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Jolynn Tumolo
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
News
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
10/07/2024
Jolynn Tumolo
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no...
10/07/2024
Neurology
A woman sits on the couch with her arms wrapped around her legs, looking unhappy
News
Comorbidity Burden May Increase Disease Activity in MS Patients
09/30/2024
Jolynn Tumolo
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in...
09/30/2024
Neurology

Migraine CME Series

News

a head in profile with a heart over where the brain would be against a teal background
News
Multiple Sclerosis May Increase Risk for Alzheimer Disease
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
In Pediatric Onset Multiple Sclerosis, Biological Aging May Be Accelerated
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
Biomarker Combo Predicts MS in Patients With Radiologically Isolated Syndrome
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
Long COVID Symptoms Persist in Individuals With Multiple Sclerosis, Study Finds
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
Injectable Medication
News
MS Drug Associated with Rare Cases of Anaphylaxis, FDA Warns
02/06/2025
Jolynn Tumolo
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare,...
02/06/2025
Neurology
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
Jolynn Tumolo
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Jolynn Tumolo
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
News
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
10/07/2024
Jolynn Tumolo
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no...
10/07/2024
Neurology
A woman sits on the couch with her arms wrapped around her legs, looking unhappy
News
Comorbidity Burden May Increase Disease Activity in MS Patients
09/30/2024
Jolynn Tumolo
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in...
09/30/2024
Neurology
FDA approval stamp
News
FDA Approves Subcutaneous Injection for Maintenance Treatment of Early AD
09/11/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug...
09/11/2025
Neurology
brain scan
News
Moderate to Severe TBI Linked With Development of Malignant Brain Tumors
09/08/2025
Jolynn Tumolo
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe...
09/08/2025
Neurology
A woman lies in bed with her mouth open snoring sleep apnea
News
New AASM Patient-Reported Outcome Tool Valid for Monitoring Sleep Apnea
09/08/2025
Jolynn Tumolo
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool...
09/08/2025
Neurology
Mediterranean diet
News
Mediterranean Diet May Mitigate Genetic Risk for Alzheimer Disease
09/05/2025
Brionna Mendoza
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4...
09/05/2025
Neurology
An illustration of a brain with a puzzle piece missing, surrounded by doctors with elderly patients
News
In Early Trial, Ambroxol Shows Promise for Parkinson Disease Dementia
09/02/2025
Jolynn Tumolo
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for...
09/02/2025
Neurology
A head in profile with cogs coming out of it against an orange background
News
Less Than a Third of Patients With Focal Epilepsy Become Seizure-Free on First ASM
08/26/2025
Jolynn Tumolo
Most patients with newly diagnosed focal epilepsy require more than 1 antiseizure medication (ASM) and more than 1 year to achieve seizure freedom.
Most patients with newly diagnosed focal epilepsy require more than 1 antiseizure medication (ASM) and more than 1 year to achieve seizure freedom.
Most patients with newly...
08/26/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
Phase 2 Trial Finds Risdiplam Effective and Safe in Newborns With SMA
08/21/2025
Jolynn Tumolo
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Infants with presymptomatic...
08/21/2025
Neurology
brain scans
News
Early Intravenous Immunoglobulins May Improve Outcomes in Anti-IgLON5 Disease
08/18/2025
Jolynn Tumolo
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Starting intravenous...
08/18/2025
Neurology
A woman lies in bed awake due to insomnia
News
Cannabinoids Produce Worse Sleep Outcomes in Small Pilot Study
08/15/2025
Brionna Mendoza
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of...
08/15/2025
Neurology
child sitting at a desk
News
Oseltamivir Reduces Risk of Serious Neuropsychiatric Events in Children During Influenza Episodes
08/13/2025
Maria Mantas
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology. 
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology. 
Oseltamivir treatment was...
08/13/2025
Neurology

Alzheimer's Disease CME Series

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use